



HAL
open science

Cell-cell fusion induced by measles virus amplifies the type I interferon response.

Florence Herschke, Sébastien Plumet, Thomas Duhén, Olga Azocar, Johan Druelle, David Laine, Timothy Fabian Wild, Chantal Rabourdin-Combe, Denis Gerlier, Hélène Valentin

► **To cite this version:**

Florence Herschke, Sébastien Plumet, Thomas Duhén, Olga Azocar, Johan Druelle, et al.. Cell-cell fusion induced by measles virus amplifies the type I interferon response.. *Journal of Virology*, 2007, 81 (23), pp.12859-71. 10.1128/JVI.00078-07 . hal-00169132

HAL Id: hal-00169132

<https://hal.science/hal-00169132>

Submitted on 8 Oct 2008

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Cell-cell fusion induced by measles virus amplifies the type I interferon**
2 **response**

3

4 F. Herschke^{1‡}, S. Plumet^{1‡}, T. Duhon^{2‡}, O. Azocar², J. Druelle³, D. Laine², T. F. Wild³, C.
5 Rabourdin-Combe^{2§}, D. Gerlier^{1§} and H. Valentin^{2§*}

6

7

8

9 ¹Interactions virus cellule-hôte; CNRS; Université de Lyon 1; FRE3011, IFR 62 Laennec, 69372
10 Lyon Cedex 08 – France

11

12 ²Interaction virus-système immunitaire; INSERM ; U851, IFR128 BioSciences Lyon-Gerland,
13 Université de Lyon 1; 21 Avenue Tony Garnier, 69365 Lyon Cedex 07 – France

14

15 ³Immunobiologie des infections virales; INSERM; U758, IFR128 BioSciences Lyon-Gerland,
16 Université de Lyon 1; 21 Avenue Tony Garnier, 69365 Lyon Cedex 07 – France

17

18 [‡] and [§] These authors equally contributed to this work

19

20 **Running title:** Amplified interferon by virus-induced fusion

21

22 * **Corresponding author:** Phone: (+33) 4 37 28 23 51

23

Fax: (+33) 4 37 28 23 41

24

Mail: valentin@cervi-lyon.inserm.fr

25

26 **Words count for Abstract size:** 246

27 **Words count for Text size (excluding abstract, references and figure legends):** 7184

ACCEPTED

29 **ABSTRACT**

30

31 Measles virus (MeV) infection is characterized by the formation of multinuclear giant cells
32 (MGC). We report that IFN- β production is amplified *in vitro* by the formation of virus-induced
33 MGC derived from human epithelial cells or mature conventional dendritic cells (mDC). Both
34 fusion and IFN- β response amplification was inhibited in a dose dependent way by a fusion
35 inhibitory peptide after MeV infection of epithelial cells. This effect was observed at both low
36 and high multiplicity of infection. While in the absence of virus replication, the cell-cell fusion
37 mediated by MeV H/F glycoproteins did not activate any IFN- α/β production, an amplified IFN-
38 β response was observed by infecting H/F-induced MGC with a non fusogenic recombinant
39 chimerical virus. Time-lapse microscopy studies revealed that MeV-infected MGC from
40 epithelial cells have a highly dynamic behavior and an unexpected long lifespan. Following the
41 cell-cell fusion, both of the RIG-I and IFN- β gene deficiencies were trans-complemented to
42 induce an IFN- β production. IFN- β and IFN- α production were also observed in MeV-infected
43 immature and mature DC (iDC and mDC). In contrast to iDC, MeV infection of mDC induced
44 MGC which produced enhanced amounts of IFN- α/β . The amplification of IFN- β production
45 was associated with a sustained nuclear localization of IFN regulatory factor 3 (IRF-3) in MeV-
46 induced MGC derived from both the epithelial cells and mDC, while the IRF-7 up-regulation was
47 poorly sensitive to the fusion process. Therefore, MeV-induced cell-cell fusion amplifies IFN-
48 α/β production in infected cells and this indicates that MGC contribute to the antiviral immune
49 response.

50 INTRODUCTION

51

52 Measles virus (MeV) is an important human pathogen responsible for ~345 000 of deaths in
53 2005 (<http://www.who.int/mediacentre/factsheets/fs286/en/>). However, most humans clear this
54 viral infection provided that they have a functional cellular and adaptive immunity (19). MeV
55 infection begins in the respiratory tract and then spreads to local lymphoid tissues, where virus
56 replication can occur in macrophages and possibly conventional dendritic cells (cDC) (14, 17, 22,
57 49, 70). This allows MeV spreading to other lymphoid organs and to the whole body. MeV
58 induces a cytopathic effect characterized by the fusion of neighboring cells into multinucleated
59 giant cells (MGC). *In vivo*, seven days after MeV infection of rhesus monkeys, MGC are found in
60 respiratory and genitourinary tract, as well as in the esophagus and skin epithelia (47). In
61 addition, a specific subset of infected MGC called Warthin-Finkeldey cells (WFC), initially
62 described in infants dying of acute measles, is found in primary and secondary lymphoid organs
63 (19). WFC are usually observed in germinal centers and interfollicular areas of secondary
64 lymphoid organs and in the thymus. They are heterogeneous and display either B or T cells
65 markers (54), although macrophage and DC markers have not yet been investigated. *In vitro*,
66 MeV infection of human cells, including primary epithelial cells and cDC, induces the formation
67 of MGC also referred to as syncytia (17, 78, 82). MeV-induced cell-cell fusion is governed by the
68 interaction of the viral envelope H and F glycoproteins with the cellular receptors CD46 and
69 CD150, which are expressed ubiquitously and solely on immune activated cells, respectively
70 (19).

71 The hallmark of the immune response to a viral infection is the rapid production of a range of
72 cytokines, most prominently type I IFN (IFN- α/β). The IFN- α/β enable cells to be protected
73 against viral infection via pleiotropic activities such as inhibition of protein synthesis and cell

74 proliferation, and enhancement of infected cell apoptosis (reviewed in (5, 21)). They also activate
75 Natural Killer (NK) cells and cytotoxic T cells (CTL) that are capable of eliminating the viral
76 pathogen by killing infected cells. The IFN- α/β can act directly on CTL or indirectly by inducing
77 the maturation of cDC, which facilitates cross-presentation of viral antigens to CTL (42, 43). The
78 single IFN- β gene and most of the IFN- α genes differ in their promoter region, the former is
79 activated by IFN regulatory factor 3 and 7 (IRF-3/IRF-7) heterodimers (56), whereas only IRF-7
80 homodimers (25) and/or IRF-7/IRF-8 heterodimers as recently reported in mouse DC (75), can
81 activate the latter. The recognition of peculiar danger molecular motifs of viruses is mediated by
82 host pattern recognition receptors (PRR) (36), which can recognize virus nucleic acids. Two
83 groups of PRR are involved in IFN production in DC, the Toll-like receptors (TLR) and the RIG-
84 like receptors (RLR). To date, TLR are mainly responsible for IFN- α production by plasmacytoid
85 DC (pDC) via TLR7 and TLR9 (1), which respond to viral nucleic acids within the endosomal
86 compartment. Nucleic acid recognition results in the activation of the IFN- α genes through the
87 phosphorylation and the nuclear translocation of IRF-7 (26, 37). Indeed, in comparison with other
88 cells, pDC express high level of IRF-7 (8, 30) and this allows pDC to produce 100- to 1000-fold
89 more IFN- β and IFN- α than other cell types (26). TLR are also involved in IFN production by
90 cDC via TLR3 after phagocytosis of infected cells (64). However, the IFN response in cDC
91 principally relies on RLR (RIG-I and MDA-5) (34, 35), which are cytosolic PRR expressed in
92 almost all nucleated cells and dedicated to respond to viral nucleic acids produced during
93 replication ((28, 60, 87). MDA-5 and RIG-I recognized dsRNA (20) and 5'-triphosphate ended
94 RNA (28, 60, 62), respectively. Accordingly, they recognize different types of RNA viruses,
95 MDA-5 being activated by *Picornaviridae* and RIG-I by *Flaviviridae*, *Orthomyxoviridae* and
96 *Mononegavirales* (20, 35). MeV activates RIG-I which recognizes the 5'-triphosphate end of the
97 small RNA leader transcript (62). The activation of RLR induces the interaction with an adaptor

98 protein called IPS-1 (also known as MAVS, VISA, CARDIF) that leads to NF- κ B, IRF-3 and
99 IRF-7 phosphorylation and their transient translocation into the nucleus, resulting in the early
100 IFN- β gene induction (34, 57). In contrast to the short-living IRF-7, the more stable IRF-3 is
101 highly expressed in all cells (25). IFN- β is then secreted and binds to the IFNAR to produce late
102 IFN- β and all IFN- α subtypes. Indeed, early IFN- β induces the transcription of numerous genes
103 known as IFN-stimulated genes (ISG) (25), including IRF-7. The activation of this supplemental
104 source of IRF-7 allows the delayed production of a boost of both IFN- β and IFN- α , according to
105 a robust positive feedback loop, which amplifies the antiviral response (25). The crucial role of
106 the RLR in the IFN- α/β response and control of viral replication has been recently highlighted in
107 IPS-1 (or MAVS) deficient mice, which show normal IFN- α secretion by pDC (41, 74).

108 In the case of MeV, IFN- α/β production has been found after *in vitro* infection of various
109 human cell types including epithelial (from various tissues), endothelial, glial and PBMC (52, 84,
110 85). MeV propagates more efficiently in mature cDC (mDC) than in immature cDC (iDC) and
111 induces higher level of MGC formation in mDC (17, 66). Given the ability of MeV to induce
112 MGC formation in epithelium and secondary lymphoid organs, we aimed at investigating, both in
113 human epithelial cells and cDC, the role of MeV-induced cell-cell fusion on the regulation of
114 IFN- α/β production.

115

116 MATERIALS AND METHODS

117

118 **Reagents.** Antibodies used were: mAbs clone 55 (anti-H), clone 25, and 120 (anti-N), G28.5
119 (anti-CD40) and rabbit polyclonal anti-human IRF-3. The following reagents were used: Hoechst
120 33342 (Sigma), fusion-inhibiting peptide FIP Z-D-Phe-L-Phe-Gly-OH (Neosystem), rhGM-CSF
121 and rhIL-4 (generously provided by Schering-Plough), rhIFN- β (Calbiochem, San Diego, CA),
122 Draq5 (Alexis Biolabs).

123

124 **Cells and phenotypic analysis.** Human kidney epithelial 293T/17 cells (ATCC) expressing
125 CD46 (293T/CD46⁺), HeLa cells, African green monkey Vero fibroblasts (ATCC),
126 293T/CD150⁺ (77), Huh7.5 cells, a subline of Huh7 defective in RIG-I (73), and human cortical
127 TEC (P1.4D6 clone) from postnatal thymus (16) were maintained in DMEM medium
128 supplemented with 10 % FCS or as described in (16, 73). Monocyte-derived DC were generated
129 *in vitro* from human blood (Etablissement de Transfusion Sanguine, Lyon, France) as previously
130 described (17). After 6 days of culture in 200 ng/ml rhGM-CSF and 10 ng/ml rhIL-4, >95% of
131 the cells were iDC. The mDC were derived by treating iDC for 48 h with 10 μ g/ml of mAb anti-
132 CD40. The cDC phenotyping was determined as previously described (17, 82).

133

134 **MeV infection.** MeV (Hallé strain) and recombinant chimerical MGV (72) were maintained
135 in Vero cells. For MeV infection experiments, cells were seeded overnight at appropriate density
136 in a 24-well plate according to the duration of the observation to avoid cell crowding. 293T and
137 TEC were infected at MOI of 1, unless otherwise indicated, then treated or not with FIP. DC
138 were infected at MOI of 0.1 with MeV as previously detailed (17, 83). As controls, all cells were

139 pulsed with a mock preparation corresponding to uninfected Vero cell supernatant. In some
140 experiments, FIP (100 µg/ml) was added to the cDC cultures infected or not with MeV.

141

142 **Transient cell transfections.** 4×10^5 293T/CD46⁺ cells were plated on 6-well plates (BD,
143 Falcon). The day after, cells were transfected either with 1 µg pCXN2-F (expressing Edm-F) plus
144 1 µg pCXN2-EdH (expressing the CD46-binding H^{Ed}) or 1 µg pCXN2-KAH (expressing the H^{KA}
145 from the wild type KA MeV isolate which does not bind to CD46) (79), or 2 µg of pBSK⁺ carrier
146 plasmid (Stratagene). All transfections were performed using Lipofectamine (Invitrogen) or
147 Dreamfect (OZ Biosciences) according to manufacturers' instructions.

148

149 **Time-Lapse.** 2×10^6 293T/CD46⁺ cells were plated on a 6-well plate and infected with MeV
150 at MOI of 1 as described above. After 24 h of culture in the presence of 10 µg/ml FIP, FIP was
151 removed and the plate was placed on a 37°C heated in 5% CO₂ atmosphere (Carl Zeiss, Jena,
152 Germany). Cells were imaged by Metamorph software v6 with a Coolsnap HQ monochrome
153 camera associated to timelapse microscope (Axiovert 100 M) and a x10 (numerical aperture 0.25)
154 Plan-Apochromat objective (Zeiss). Meta Imaging Series 4.5 (Universal Imaging, West Chester,
155 PA) was used to make Quick-Time movies from image stacks from metamorph software. One
156 picture was made every 10 min for 60 hours and every second of movie represent 235.4 min
157 (3.92 h) of culture (see Fig. S5video.mov). Images extracted from stacks were processed with
158 Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA).

159

160 **Co-culture experiments.** 8×10^4 Huh7.5 and Vero cells were plated in 24-well plates
161 (Costar) and were infected, 24 h later, with MeV at MOI of 1. At 8 h.p.i., Vero cells were
162 trypsinized and added to the Huh7.5 cell monolayers at a 1:1 ratio, in the presence or absence of

163 10 µg/ml of FIP. Cell-free supernatants were harvested at different times and frozen before
164 analysis for IFN- α/β using a biological assay.

165

166 **IFN- α and IFN- β detection assay.** IFN- α/β contents in supernatants were determined using
167 a bioassay as detailed elsewhere (84). IFN- α and IFN- β were determined by ELISA using the
168 IFN-alpha kit from Bender MedSystems (detection limit = 8 pg/ml), and the IFN-beta kit from
169 PBL Laboratories (detection limit = 250 pg/ml), respectively.

170

171 **RNA extraction, cDNA RT, and real-time QPCR analysis.** A detailed procedure can be
172 found for viral RNA quantification in (61). Primer sets for human IFN- β and IRF-7 mRNA
173 quantitation were forward TGGGAGGATTCTGCATTACC, and reverse
174 CAGCATCTGCTGGTTGAAGA primers, respectively. The primer sets were purchased from
175 Search-LC (Heidelberg, Germany). Results were normalized according to the amounts of 18S
176 rRNA, and expressed in mRNA copy number / 25 ng of total RNA.

177

178 **MTT colorimetric bioassay.** 4×10^3 293T/CD46⁺ cells were plated in a 96-well plate
179 (Costar). At 30 h after infection or transfection, cells were treated with 225 ng/well of 3-(4,5-
180 dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma) to measure
181 mitochondrial activity of metabolically active cells. 4 h later, the supernatant was removed and
182 the cells were lysed with 100 µl/well DMSO containing 0.04 N HCl. Absorbance was then
183 measured at 490 and 650 nm (18).

184

185 **Quantitative fusion assay.** This assay is based on the conditional expression of β -
186 galactosidase (β -Gal) under the control of the T7 polymerase promoter and was performed as
187 previously described (7).

188

189 **Subcellular localization of GFP-IRF-3 proteins.** 5×10^4 293T/CD46⁺ cells, seeded in 24
190 well plate were infected or not with MeV at MOI of 1 for 2 h then transfected by the GFP-IRF-3
191 expression plasmid (46) using lipofectamine. 24 to 48 h latter, GFP-fluorescence in living cells
192 was analyzed with a Leica DM IRB microscope at a magnification of x400. The percent of IRF-
193 3-labeled nuclear was calculated by counting, within a microscope field, the total number of
194 nuclei (belonging to mononuclear cells or MGCs, labeled and unlabeled,) and the number of
195 nuclei labeled with GFP-IRF-3. In each condition, >100 nuclei were counted.

196

197 **Stainings.** For nuclear staining, cell monolayers were stained with Hoechst 33342 as detailed
198 previously (82) and the stained nuclei were observed using a Leica DM IRB microscope.

199 MeV H cell surface expression was detected using c155 mAb plus goat anti-mouse IgG
200 phycoerythrin-conjugated secondary antibody (GAM-PE), (Jackson ImmunoResearch
201 Laboratories) as previously described (82). MeV N intracellular detection was performed using
202 Cytotfix/Cytoperm kit (Becton Dickinson, Parsippany) and 293T/CD46⁺ cells were labeled using
203 biotinylated c125 mAb plus streptavidin-PE (Caltag Laboratories) as previously described (82).
204 After labelling, cells were analyzed using a FACScalibur flow cytometer (Becton Dickinson
205 Cellquest software). Integrated fluorescence was measured, and data were collected from at least
206 5,000 events.

207 Triple stainings were performed to visualize GFP-IRF-3 (green), MeV N protein (red) and
208 nuclei (blue) by confocal microscopy assays. 2.5×10^4 293T/CD46⁺ cells were seeded onto pre-

209 coated poly-L-Lysine (Sigma, 10 µg/ml, overnight at 4°C) glass coverslips in a 24-well plates
210 and incubated 20 min at 37°C. 12 h later, cells were infected with MeV at a MOI of 0.1, 1, 2 and
211 4, followed by transfection of the GFP-IRF-3 expression plasmid as described above, and then
212 cultured in the absence or the presence of FIP at 10µg/ml. 48 h later, cells were fixed in 2%
213 paraformaldehyde/PBS for 20 min at room temperature, treated with 0.1% Glycine/PBS for 10
214 min at room temperature, and permeabilized with 0.5% Triton X-100/PBS for 5 min at room
215 temperature. After washes with PBS, the fixed cells were blocked in BSA, human and goat
216 serums, Triton X-100/PBS overnight at +4°C. Cells were then incubated with cl120 anti-N mAb
217 for 90 min at +4°C. Cells were washed 3 times for 5 min in PBS before incubation with a GAM-
218 Alexa 568 for 30 min at +4°C. After 3 washes in PBS, cells were mounted on glass slides with
219 mounting medium (Dako) containing Draq5 as nuclear marker. Labeled cells were imaged with a
220 confocal microscope (Zeiss LSM510, 1 µm) using a zoomed (x2) 63X (NA 1.4) PlanFluor
221 objective. To prevent cross-contamination between fluorochromes, each channel was imaged
222 sequentially using a multi-track recording module before merging.

223 Double staining was performed to visualize endogenous IRF-3 (green) and nuclei (blue) by
224 Axioplan2 Imaging microscopy assays. Briefly, 8×10^4 mDC were seeded onto pre-coated poly-L-
225 Lysine glass coverslips in a 24-well plates and incubated 20 min at 37°C. 24h later, cells were
226 infected at a MOI of 0.1, and then cultured in the absence or the presence of FIP at 100µg/ml. At
227 3 d.p.i., cells were then fixed as for triple staining. Then, the fixed cells were blocked in
228 BSA/serums/Triton X-100/PBS for 1 h at +4°C and incubated with rabbit anti-IRF-3 serum for 1
229 h at +4°C. Cells were washed 3 times for 5 min in PBS before incubation with a goat anti-rabbit
230 IgG Alexa 488-conjugated secondary antibody (Molecular Probes) for 30 min at +4°C. After 3
231 washes in PBS, cells were incubated with 1 µg/ml of Hoechst 33343 for 15 min at room
232 temperature before mounted on glass slides with mounting medium (Dako). Labelled cells were

233 analyzed with an Axioplan2 Imaging microscope (Zeiss, 0.3 μm) and then imaged by metamorph
234 software V6. Images extracted from Z stacks were processed with Adobe Photoshop 6.0
235 software.

236

237 RESULTS

238 **MeV-induced cell-cell fusion amplifies IFN- β activation in epithelial cells.** While MeV
239 induced a high number of syncytia containing numerous nuclei in cells expressing both MeV
240 receptors (293T/CD46⁺CD150⁺), syncytia were smallest and less numerous in 293T/CD46⁺ cells
241 expressing only CD46 (not shown). MeV infection of 293T/CD46⁺ cells led to the accumulation
242 of F viral transcripts and to the induction of IFN- β gene expression (data not shown). The
243 accumulation of viral F mRNA and the transcription of the IFN- β gene were both enhanced in
244 293T/CD46⁺CD150⁺ cells, compared to 293T/CD46⁺ cells (data not shown). Thus, the level of
245 IFN- β activation was correlated to the virus transcription and/or to the cytopathic effects.

246 To decipher how each of these could influence the IFN response, we took advantage of the
247 availability of a fusion inhibitory peptide (FIP). FIP efficiently blocks the MeV-induced syncytia
248 formation without inhibiting the cell-to-cell virus spreading (19). Addition of FIP repressed both
249 syncytium formation and IFN- α/β production in MeV-infected 293T/CD46⁺ culture, without
250 affecting the proportion of cells expressing MeV-N protein (Fig. 1A, left histogram). Whereas the
251 fusion was totally inhibited by FIP, the IFN- α/β production by day 3 (not shown) and 7 p.i. (Fig.
252 1A, left histogram) was inhibited by ~85-96%. This residual IFN- α/β production was significant,
253 since no IFN- β could be detected in uninfected cells (data not shown). However, 293T cells
254 expressing only MeV-Ed-H and -F glycoproteins readily fused into MGC, but did not secrete any

255 detectable IFN- α/β (data not shown). This indicates that cell-cell fusion, *per se*, does not activate
256 the IFN- α/β response.

257 A recombinant chimerical virus, MGV, where H and F genes have been substituted by that of
258 the VSV G glycoprotein (72), infected and propagated more slowly in 293T/CD46⁺ cells without
259 inducing syncytium formation. Accordingly, it induced a low level of IFN- β production which
260 was insensitive to FIP (Fig. 1A, right histogram), and equivalent to that observed in FIP-treated
261 MeV-infected 293T/CD46⁺ cells. Thus, MGV only triggered a basal level of IFN- α/β response,
262 in agreement with the observation of the low IFN- α/β inducing ability of a non-fusogenic MeV
263 variant (48). To confirm the enhancing effect of cell-cell fusion on MeV-induced IFN- β response,
264 we compared the effect of expressing *in trans* a fusing (H^{Ed}F) and a non fusing (H^{KA}F) (79)
265 glycoprotein combination on the IFN- β response induced by MGV infection. As expected, the
266 expression of H^{KA}F did affect neither virus nor IFN- β transcription (not shown). In contrast,
267 when compared to H^{KA}F, the expression of H^{Ed}F induced large syncytia into 293T/CD46⁺ cells, a
268 minor increase of viral transcription and a significant increase in the IFN- β gene activation (Fig.
269 1B). Furthermore, the enhancing effect on the IFN- β response was much more pronounced in
270 conditions ensuring that every single got infected, i.e. at MOI of 4, with a ~25 fold enhancement
271 of IFN- β mRNA accumulation, compared to a limited 2.5 fold increase in virus transcript
272 accumulation.

273 When 293T/CD46⁺ cells were infected with fusogenic MeV at MOI ranging from 0.01 up to
274 4 and analyzed at 30 h.p.i., the viral transcription of the F messenger exhibited a dose-response
275 curve between MOI of 0.01 and 1 then reached a plateau (Fig. 1C, upper histograms). The
276 identical level of viral transcription between MOI of 1 and 4 suggested that some viral
277 interference occurred. In addition, at MOI higher than 1, a cytotoxicity, increasing with the MOI
278 used, was observed, that likely resulted in part from cell fusion from without (i.e. fusion between

279 adjacent cells bridged by viral particles) (6), a reminder of viral induced hemolysis of CD46
280 expressing Vervet monkey red blood cells (59). Furthermore, syncytia formation was much
281 reduced when compared to lower MOI likely because of the strong down-regulation of CD46
282 upon contact with the large amount of the hemagglutinin brought about by the high viral
283 inoculum (39, 51). The level of IFN- β transcription followed the same dose-response between
284 MOI of 0.01 and 1, to reach a plateau at MOI of 1, 2 and 4 (Fig. 1C, middle histograms). This
285 correlation between viral transcription and IFN- β gene activation agrees with their parallel
286 kinetics observed at MOI of 1 (62). Surprisingly, the production of IFN- α/β in the supernatant
287 measured at 3 d.p.i. was almost identical between MOI of 0.1 and 4 (Fig. 1C, lower histograms).
288 At MOI of 0.01, a small amount of IFN- α/β was detected only later at 7 d.p.i. (data not shown).
289 The addition of FIP, which inhibited the formation of syncytia at all MOI (Fig. 1C), had minimal
290 effects on viral transcription, but strongly inhibited IFN- β gene transcription and protein
291 secretion (Fig. 1C, black columns), except at MOI of 4. Interestingly, in the presence of FIP, the
292 amount of IFN released in the supernatant and the MOI correlated for MOI between 0.1 and 2
293 (Fig. 1C and data not shown). At MOI of 0.01, the level of IFN released detected at 7 d.p.i. was
294 also inhibited by FIP (not shown). The lack of FIP inhibitory effect at MOI of 4 was likely
295 reflecting the side effects of the too high viral load mentioned above.

296 Furthermore, after infection at MOI of 1, FIP inhibition of the cell-cell fusion observed at 30
297 h.p.i. and 3 d.p.i., was dose-dependent as assessed by nucleus staining with Hoechst 33342 (Fig.
298 2A, and data not shown), and the quantification assay using β -Gal as a reporter gene for
299 intercellular fusion (Fig. 2B). A similar inhibition curve was also observed for the IFN- β mRNA
300 (Fig. 2C and not shown). Strikingly, the best mathematical equation describing these two dose-
301 dependent responses had similar slopes (-11) and ordinates at the origin (+42 and +39).

302 In summary, MeV replication triggers a basal IFN- β response independently of H/F proteins
303 and MeV-induced cell-cell fusion robustly amplifies this response in a dose-dependent manner at
304 both low and high MOI.

305

306 **High morphologic plasticity of MeV-induced MGC.** Viral induced fusion is usually
307 correlated with apoptosis (13). As we observed an increased synthesis of IFN- β in MGC, we
308 further analyzed the morphological plasticity of these cells. Thirty hours p.i., syncytia were found
309 to be metabolically active, and able to convert MTT into intracellular formazan crystals, a
310 hallmark of mitochondrial activity in viable epithelial cells (data not shown).

311 Studies by time-lapse microscopy over 60 hours of MeV-infected 293T/CD46⁺ cells, showed
312 the syncytia to be dynamic, exhibiting a morphology which varied with time (Fig. 3A, B and Fig.
313 S3Avideo.mov). In the 1st stage, the initial flat adherent syncytium increased in size and nucleus
314 contents (Fig. 3A, Adherent). Dynamic pseudopodia emerged from the syncytium to contact
315 surrounding cells or syncytia. In a 2nd stage, the adherent syncytium retracted into highly
316 refringent smooth balls (3rd stage), where nuclei were no longer visible, except upon examination
317 under confocal microscopy of z-stacks after Hoechst staining (see below). Balls were highly
318 mobile and rolled around. When they encountered surrounding healthy adherent mononuclear
319 cells, they spread out into a secondary flat adherent syncytium with visible nuclei (4th stage).
320 Then, the secondary adherent syncytium retracted again (5th stage), into an irregular ball with
321 protruding blisters giving them a cauliflower appearance (6th stage), which rolled around. The
322 duration of each stage was highly variable (see mean values on Fig. 3B), and most of the initial
323 syncytia passed through stages 1, 2 and 3, half of them passed through stages 4 and 5 to reach
324 stage 6, and another half directly passed from stage 3 to stage 6 (Fig. 3B). Of 17 initial syncytia
325 recorded during 3 different experiments, none appeared to die before 60 hours. Furthermore,

326 when individual smooth or blistered balls were transferred onto a fresh uninfected 293T/CD46⁺
327 monolayer, they re-adhered. This suggests that syncytia may have an indefinite lifespan provided
328 that they find within their vicinity a healthy cell monolayer (Fig. 3B, and data not shown). In
329 contrast, when transferred to a plastic dish covered or not by collagen, both smooth and blistered
330 balls became senescent and finally died to become floating and optically clear bubble-like
331 structures (data not shown). Thus, MeV-induced syncytia are not prone to quickly die; instead,
332 they may remain a viable entity. As controls, cell-to-cell fusion was observed neither in
333 uninfected nor in FIP-treated MeV-infected 293T/CD46⁺ cells, indicating that none of the
334 observed syncytium was due to merging senescent 293T/CD46⁺ cells (Fig. 3C and data not
335 shown).

336

337 **Cell-cell fusion brings together both danger activation signal and IFN- β gene to trigger**
338 **IFN- β induction.** We then studied whether MeV-induced fusion can trigger trans-
339 complementation using Huh7.5 cells and Vero cells which have disabled RIG-I (73) and lack the
340 IFN- β gene (11, 12), respectively. IFN- α/β was secreted and accumulated over time from both of
341 the MeV-Huh7.5/Vero and MeV-Vero/Huh7.5 cell co-culture combinations, as syncytia were
342 observed (Fig. 4). Moreover, the addition of FIP completely blocked both of the cellular fusion
343 and the IFN- α/β production to undetectable levels. As expected, MeV infection of isolated
344 Huh7.5 or Vero cells induced syncytia but did not trigger any IFN- α/β response. Thus, the RIG-I
345 defect in human Huh7.5 cells and IFN- β gene defect in the simian Vero cells could be trans-
346 complemented in fused cells allowing the triggering of the human IFN- β gene.

347

348 **IRF-7 expression level is not influenced by MeV-induced fusion in epithelial cells.** We
349 then investigated whether the enhancement of IFN- β gene expression mediated by MeV-induced

350 cell-cell fusion correlate with the up-regulation of IRF-7. To this end, the level of IRF-7
351 transcripts was analyzed in 293T/CD46⁺ cells and in the primary thymic epithelial cells (TEC),
352 which are IFNAR-competent, in the presence or the absence of FIP (Fig. 5). In both of these cell
353 types, MeV infection resulted in the activation of the IFN- β and IRF-7 genes. However, the level
354 of IRF-7 transcripts remained unchanged when syncytia formation was blocked by FIP treatment,
355 and did not correlate with the IFN- β mRNA level. Thus, the amplification of IFN- β activation by
356 MeV-induced cell-cell fusion is not directly or solely controlled by the level of IRF-7 expression.

357

358 **MeV-induced cell-cell fusion amplifies IFN- α and IFN- β responses in human mDC, but**
359 **not iDC.** The phenomenon of the amplification of the IFN- α/β response by MeV-induced cell-
360 cell fusion was then examined in human monocyte-derived DC. More than 95% of iDC and mDC
361 were CD1a⁺ and CD14⁻ (data not shown). While the immature phenotype was confirmed by the
362 low or negative expression of MHC class II, CD83, CD40, CD80 and CD86, mDC expressed
363 high level of these molecules (data not shown). In agreement with previous reports (17, 50), both
364 iDC and mDC, which have a CD46⁺CD150^{Low} and CD46⁺CD150^{High} phenotype, respectively
365 (Fig. 6A) (50), were sensitive to MeV infection as shown by MeV-F transcription (Fig. 6B).
366 However, the sensitivity to infection differed between iDC and mDC. MeV replication was faster
367 in mDC in comparison with iDC with ~230-fold higher transcription at 3 d.p.i. (Fig. 6B). While
368 the iDC only poorly fused, the MeV-infected mDC contained numerous giant MGC (Fig. 6),
369 which expressed both viral proteins and mDC markers ((17), and data not shown). The addition
370 of FIP to the cDC did not significantly affect the MeV-F transcription in the iDC and only
371 partially reduced the MeV-F transcription in the mDC (Fig. 6B), while FIP efficiently inhibited
372 the formation of MGC (Fig. 6). We then investigated the IFN- α/β production in cDC following
373 MeV infection. MeV-infected iDC secreted significant levels of bioactive IFN- α/β (Fig. 6C) and

374 IFN- α (Fig. 6D). No IFN- β production was detected (Fig. 6E), even though IFN- β transcripts
375 were observed (Fig. 6F), because of either the limited sensitivity of the ELISA, or the
376 consumption of IFN- β by MeV-infected iDC (25). According to the very low level of cell-cell
377 fusion observed within MeV infected iDC, the addition of FIP did not affect the IFN- α/β
378 production (Fig. 6C and D). The MeV infected mDC produced significant levels of bioactive
379 IFN- α/β , IFN- α , and IFN- β (Fig. 6C-E) and IFN- β mRNA (Fig. 6F). Both the MGC formation
380 and IFN- α/β production by MeV-infected mDC was strongly inhibited in the presence of FIP
381 (Fig. 6C-F). Thus, the MeV infection induces IFN- α/β responses in both of the iDC and mDC.
382 However, the virus-induced cell-cell fusion amplifies both the IFN- α and IFN- β production only
383 in mDC. Interestingly, MeV infection induced an IRF-7 up-regulation in the iDC, but not in mDC
384 (Fig. 6G). Furthermore, FIP did not significantly affect the expression of IRF-7 in both DC types
385 (Fig. 6G).

386 As a control, the non fusiogenic chimerical virus MGV was also used to infect iDC and
387 mDC. MGV only induced, in both iDC and mDC, a basal IFN response, which was not sensitive
388 to FIP (data not shown). We noticed that, contrary to MeV, MGV replicated better in iDC than in
389 mDC (Fig. 6A) and, accordingly, induced a stronger IFN- β gene transcription in iDCs. We
390 speculate that the stronger endocytosis ability of iDC over mDC can favor MGV entry, which
391 relies on the acidic endosomal pathway mediated by the VSV-G glycoprotein.

392 Thus, MeV infection induces IFN- α/β responses in both iDC and mDC. However, the virus-
393 induced cell-cell fusion amplifies both IFN- α and IFN- β production only in mDC.

394

395 **Sustained nuclear translocation of IRF-3 in MeV-induced MGC derived from epithelial**
396 **cells and mDC.** MeV infection induces transactivation of the IFN- β gene through the
397 phosphorylation and nuclear translocation of IRF-3 (65). Therefore, we analyzed the changes in

398 the subcellular IRF-3 localization using a GFP-tagged IRF-3 (GFP-IRF-3) transfected into
399 293T/CD46⁺ cells. As expected (46), the GFP-IRF-3 was localized exclusively within the
400 cytoplasm of uninfected cells (Fig. 7A, mock). After MeV infection, nuclei from a single
401 syncytium exhibited a diverse level of GFP-IRF-3 staining, thus looking asynchronous, and a
402 large proportion of syncytia contained nuclear IRF-3 whichever their stage. In addition, few
403 mononuclear MeV-infected cells surrounding outside MGCs displayed nuclear localization of
404 GFP-IRF-3 (not shown). In the absence of FIP, 50±24% of the nuclei belonging to MGC were
405 labeled with GFP-IRF-3, whereas, only 6±7% of the small amount of single cells, which
406 remained outside MGC, had their nuclei labelled (Fig. 7A, MeV). In the presence of FIP,
407 although most cells were infected (see Fig. 1A, 7B and S7B), nuclear translocation of GFP-IRF-3
408 was observed only in 4±2% of them (Fig. 7A, MeV+FIP, 2 α =0.01 when compared to 50±24 % of
409 nucleus labelling in the absence of FIP. In all cases, the nuclei were intact, including those in
410 syncytia, as shown by Hoescht staining (Fig. 7A).

411 Confocal analysis of GFP-IRF3 distribution in 293T/CD46⁺ cells infected with MeV at MOI
412 of a 1 and 2 confirmed the high rate of nuclear IRF-3 labeling in MGC compared to mononuclear
413 cells, and the presence of cytoplasmic N protein in all but rare cells, (data not shown). At the
414 lower MOI of 0.1, similar results were obtained. Upon confocal analysis, many nuclei within
415 MGC were labeled with GFP-IRF-3, whereas GFP-IRF-3 remained excluded from the nuclei of
416 non infected cells (Fig. 7B, and data not shown). When the fusion was prevented by the addition
417 of FIP, only few mononuclear cell nuclei displayed GFP-IRF3 labelling, although most of them
418 were clearly infected as shown by cytoplasmic N labeling (Fig. 7B red dots and patches, and data
419 not shown). Again, GFP-IRF-3 was translocated into the nuclei of MGC at all stages of the
420 adherent-ball cycle described in Fig. 3 (Fig. 7B and data not shown). Interestingly, the
421 distribution of both N and GFP-IRF-3 tended to change with the morphological stage of the
422 MGC. When the syncytium was flat and adherent, GFP-IRF-3 showed dotted and/or reticulated

423 distribution in the nuclei and N protein had a dotted cytoplasmic distribution. When the
424 syncytium underwent retraction into a smooth ball, the intensity of the nuclear GFP-IRF-3
425 labeling became stronger and more diffuse and N protein tend to aggregate further into larger
426 patches at the periphery of the cytoplasm (Fig. 7B, and data not shown). Thus, the amplification
427 of IFN- β production induced by MeV-mediated fusion correlates with a sustained and strong
428 nuclear translocation of IRF-3 within MGC at all their morphological stages.

429 Localization of endogenous IRF-3 during infection of mDC was also studied. As expected,
430 endogenous IRF-3 distributed exclusively within the cytoplasm of uninfected mDC (Fig. 7C,
431 mock, left panels). At 3 d.p.i., IRF-3 (green) staining of many intact nuclei (blue stain) in
432 syncytia MeV-infected mDC was observed (Fig. 7C, right panels, and supplemental material Fig.
433 S7Cvideo.mov). Interestingly, the distribution of endogenous IRF-3 in the nuclei of mDC-
434 derived syncytia looked very similar to that of GFP-IRF-3 in nuclei of 293T-derived syncytia
435 (compare Fig. 7C with 7A, B and data not shown). Addition of FIP strongly inhibited both MeV-
436 infected MGC from mDC and nuclear localization of endogenous IRF-3 (Fig. 7C, middle panel).
437 Thus, endogenous IRF-3 tended to remain translocated into nuclei within MGC from MeV-
438 infected mDC in agreement with the sustained nuclear translocation of exogenous GFP-IRF-3
439 within MGC derived from epithelial cells.

440

441 **DISCUSSION**

442

443 We report here that MeV-induced MGC or syncytia derived from epithelial cells and
444 mDCs are metabolically active, long living and display both sustained nuclear translocation of
445 IRF-3 and enhanced activation of the IFN- β gene. (i) There is a correlation between the fusogenic
446 activity of MeV strain and IFN- β production. (ii) The fusion enhancing effect is observed at both

447 low and high MOI. (iii) The fusion inhibitory peptide FIP inhibits, in a dose dependent manner,
448 both cell-cell fusion and IFN- β production. (iv) Cell-cell fusion mediated by MeV-H and -F
449 glycoproteins does not activate any IFN- β response in the absence of viral infection, but does it
450 after infection with MGCV, a non-fusiogenic chimerical virus. (v) The cytosolic PRR RIG-I and
451 the IFN- β gene are trans-complemented during the fusion process. (vi) Although both iDC and
452 mDC are infected by MeV, only mDC undergo massive cell-cell fusion. In the mDC, a robust
453 IFN- α/β production is mediated by MeV-induced cell-cell fusion (vii) In both epithelial cells and
454 mDC, the fusion enhancing effect on IFN- β response appears to be mediated by a sustained
455 nuclear IRF-3 localization, but does not directly correlate with the up-regulation of IRF-7
456 expression. (viii) In response to MeV, iDC also produces an IFN- α/β production, but it is
457 independent of the fusion process and likely amplified via IRF-7. Altogether, our results indicate
458 that the MeV-induced MGC in epithelial cells and mDC are important sources of IFN- α/β and
459 that the fusion can mediate an enhancement of IFN- α/β production without modulating the
460 expression of IRF-7.

461 Cell-cell fusion is a hallmark of many viral infections, and resulting MGC were thought to
462 be short lived. Indeed, syncytia induced by the HIV-1 glycoprotein died by apoptosis by at least
463 three different mechanisms: transient lipid exchange, activation of several kinases and
464 transcription factors and contagious apoptosis (58). Surprisingly, MeV-induced MGC from
465 epithelial cells were found to be viable and dynamic entities, capable of transducing intracellular
466 signals throughout their morphological stage changes. Thus, from our *in vitro* observations, we
467 can predict that the physiopathological MGC (WFC) observed in lymph nodes and thymus from
468 MeV-infected children and primates should have a rather long lifespan *in vivo* (54, 76). However,
469 as described by us and others (13, 58, 63, 82), syncytium apoptosis finally occurs, probably
470 depending on cellular environment deprivation.

471 In non-pathological situations, the contents of a cell nucleus should be tightly regulated to
472 ensure that every cell harbors a single nucleus. Notable exceptions are the fusion of cellular
473 precursors undergoing a specific maturation process, such as the myotubes, the osteoclasts, and
474 the syncytiotrophoblasts. In the two latter cases, a survival program is turned on (15, 31).
475 Whether such a mechanism occurs for the survival of MeV-induced MGC remains to be
476 determined. Strikingly, both of the MeV-induced MGC and syncytiotrophoblasts need to recruit
477 fresh mononuclear cells in order to survive (29). Furthermore, given that IFN- β is used as a retro-
478 control feedback to limit the size of the osteoclasts by preventing further recruitment of new
479 mononuclear cells (9), it could also regulate the dynamics of MGC formation induced by MeV as
480 observed for other viruses (53, 80, 81, 86).

481 The MeV induced cell-cell fusion results in MGC harboring an important function in the
482 innate immunity, and it could be questioned if the fusion *per se* acts as an activation signal.
483 Indeed, the artificial fusion of a human cell line with chicken erythrocytes results in the activation
484 of both human and chicken IFN- β (23), the latter being indicative of a reactivation of the dormant
485 chicken erythrocyte nucleus. The MeV induced cell-cell fusion is mediated by the H binding to
486 the CD46 or CD150 cellular receptor which results in the activation of the fusion F protein (19).
487 The H binding to CD46 has been reported to activate the IFN- β response and NO[•] production in
488 murine macrophages expressing human CD46 (33). In human epithelial cells, the H/F and CD46-
489 mediated fusion *per se* was unable to trigger the IFN- β response, which required virus
490 transcription (62). Likewise, we can exclude that the interaction of H with TLR2 is involved in
491 the IFN- β activation since (i) the signaling downstream to TLR2 occurred independently of the F
492 glycoprotein, (ii) the use of a wild type MeV with H protein unable to bind to CD46 and TLR2
493 (4) gave similar results (not shown), and (iii) the TLR2 signaling pathway is not linked to IFN-

494 α/β production. Altogether, MeV-induced cell-cell fusion in human epithelial cells is not directly
495 sensed as a danger signal by the innate cellular machinery.

496 MeV infection of human epithelial cells triggers the production of IFN- β , which is
497 differentially regulated in mononuclear cells and MGC. At the beginning of the viral infection,
498 the activation of IFN- β occurs in MeV-infected mononuclear cells where the cytosolic RIG-I is
499 activated upon recognition of the 5'-tri-phosphate end of MeV leader RNA (62), and this results
500 in the activation of IRF-3. Then, IRF-3 undergoes phosphorylation, homo- or hetero-
501 dimerization, nuclear translocation, fixation on IFN sensitive responsive elements (ISRE) and
502 degradation by the ubiquitin-proteasome pathway (3, 65). In a later phase, the amplification of
503 IFN- β production in MeV-infected mononuclear epithelial cells can be mediated by the classical
504 IFNAR/IRF-7-dependent positive feedback, as described for other viruses (27), since IRF-7 is
505 up-regulated after MeV infection. In contrast, the robust IFN- β production mediated by MGC
506 from epithelial cells could not be explained solely by the IRF-7 up-regulation, because the latter
507 was poorly sensitive to the fusion process. As described for an infection with respiratory
508 syncytial virus, IRF-3 nuclear translocation occurs early within few hours after infection, then it
509 drops rapidly within 15 hours because of the anti-interferon activity of non structural proteins
510 (71). Therefore, the presence of a high IRF-3 nuclear translocation within MGC at a late time (30
511 h.p.i.) of the MeV infection is unexpected and supports an essential role of IRF-3 in the MGC-
512 mediated amplification of the IFN- β production. It is possible that MeV proteins with IFN
513 antagonist activity are diluted out upon fusion of MGC with uninfected cells, thus allowing a
514 stronger and more sustained IFN production. It remains to be determined if the sustained IRF-3
515 nuclear localization within MGC occurs as phosphorylated IRF-3 homodimers or IRF-3/IRF-7
516 heterodimers.

517 What could be the mechanism, which enables cell fusion to boost the IFN- β activation ?
518 At low MOI (virus to cell ratio <1) of infection, we propose the following model. Since the RIG-I
519 and IFN- β gene locus are trans-complemented during the cell-cell fusion, syncytia formation can
520 boost IFN- β transcription by bringing uninfected cells into contact with viral PAMPs. At a given
521 time, the level of IFN- β activation results from the balance between available trigger viral RNA
522 (PAMPs), RIG-I (PRR), pathway components (i.e. IRF-3) and viral IFN antagonists. The
523 sustained nuclear localization of IRF-3 in the nuclei within syncytia at low MOI is compatible
524 with the continuous recruitment of non infected cells which can result either in a weaken
525 concentration of viral antagonists, and/or the recruitment of “naive” RIG-I/pathway components
526 molecules by MeV leader RNA which would be produced in excess over the amount of RIG-
527 I/pathway components available in a single cell. At high MOI, an alternative model should be
528 made since all individual cells get infected prior to the fusion event and the fusion-mediated
529 amplification of the IFN- β response is even higher (see Fig. 1B). The IRF-3 nuclear translocation
530 could be sustained within MeV-induced MGC, because of a synergistic activity such as
531 stabilization of phosphorylated IRF-3 by activation of the DNA-dependent protein kinase (DNA-
532 PK) (32). This will require further investigations. Presently, our data thus argue for two non
533 exclusive mechanisms involved in the fusion enhancing effect on IFN- β activation, one,
534 evidenced at low MOI, is the recruitment of non infected cells to MeV-infected MGC, and the
535 other, at high MOI, is a synergistic effect of cell fusion and virus infection. In both cases, there is
536 a sustained nuclear translocation of IRF-3 within MGC, the underlying mechanism of which
537 remains to be more deeply examined. In every case, the amplification of IFN- β response by MGC
538 derived from MeV-infected epithelial cells upgrades the alert level of the innate immune response
539 against viral infection in peripheral tissues.

540 During natural infection, MeV infects lung epithelial cells and/or resident iDC in epithelia
541 and mucosa, and likely induces local IFN- α/β production, which could limit MeV replication
542 (45). Then, infected iDC can migrate and disseminate the virus to the draining lymph nodes.
543 There, they can be stimulated via CD40L by encountering naive T lymphocytes and become
544 activated and more permissive to MeV replication as shown experimentally (66). Because the
545 mDC are prone to fuse with surrounding cells, they form MGC, which could correspond to the
546 WFC found in lymphoid organs. This results in a high virus progeny, which can propagate
547 throughout the body. There are several examples of IFN- α/β production by human or mouse iDC
548 (2, 34, 35) infected *in vitro* by few viruses, including MeV (38). Here, we demonstrate that upon
549 MeV infection, both of the iDC and mDC produce IFN- β and IFN- α *in vitro*. The iDC display
550 low permissiveness to MeV infection, and rapidly produce high levels of IFN- α and IFN- β
551 independently of cell-cell fusion, probably through IFNAR/IRF-7 signaling as judged by the up-
552 regulation of IRF-7 expression. Since, IFN- α/β is quickly produced and secreted by iDC after
553 infection with MeV (not shown), IFN- α/β can protect cells against the propagation of MeV and
554 strongly limit the formation of MGC. As iDC are present in peripheral tissues and secrete IFN-
555 α/β , they can contribute to the establishment of the innate antiviral state by enhancing
556 cytotoxicity of NK cells and activating macrophages (10, 40). In addition, the iDC constitute a
557 critical link between innate and adaptive immunity (44, 67). Indeed, the IFN- α/β induce the up-
558 regulation of co-stimulatory molecules CD80, CD86 and CD40 on cDC (24), and the expression
559 of TRAIL on iDC, which become cytotoxic (83). Thus, the IFN- α/β produced by MeV-infected
560 iDC is a signal which upgrades the alarm level of the cellular innate immunity for detecting the
561 invasion of a possible pathogen.

562 In contrast to the iDC, the mDC are highly susceptible to MeV infection, form large MGC
563 and produce high levels of IFN- α/β . The IFN- α/β is therefore less efficient in limiting MeV

564 growth and MGC formation within the mDC than within the iDC. The opposite phenotypes of
565 iDC and mDC could originate from different relative kinetics of the infection and the innate
566 antiviral response. Indeed, when the strength of the initial activation of IFN- β is too low
567 compared to the virus growth kinetics, the rapid accumulation of MeV encoded anti-IFN α/β and
568 possibly C proteins can block the intracellular IFNAR signaling pathway (55, 69), and this paves
569 the way for unlimited virus growth. We therefore favor that the MGC can be promoted or
570 repressed according to the respective speed and strength of virus growth and IFN- α/β production.
571 Upon infection, the mDC produce IFN- α/β mostly from MGC, without any IRF-7 up-regulation.
572 This suggests that the IFNAR/IRF-7 feedback loop is not directly involved. This data is in
573 agreement with the down-regulation of IFNAR in cDC upon their maturation (68). As for
574 epithelial cells, the robust production of IFN- α/β by the MeV-mediated MGC from mDC also
575 correlated with a sustained activation of IRF-3. However, the induction of IFN- α independently
576 of IRF-7 up-regulation in the MGC is questionable and the mechanism remains to be determined.
577 The IFN- α/β produced by MGC from MeV-infected mDC could rather be involved in the
578 establishment of MeV-specific adaptive immune response in the secondary lymph nodes. By
579 providing high viral antigen load and IFN- α/β -dependent enhancement of the cross-priming to T
580 cells (43), the paradoxical accumulation of virus and IFN- α/β within the MeV-mediated MGC
581 probably contributes to the stimulation of the MeV-specific adaptive immune response, which
582 will finally clear the virus from the organism. Finally, because of the different abilities of various
583 laboratory, vaccine and wild type MeV to counteract the cellular innate immunity, the virus strain
584 dependency of cell fusion-mediated amplification of the IFN- α/β response is also currently under
585 investigation.

586

587 **ACKNOWLEDGMENTS**

589 We thank Drs C. Servet for helpful discussions, and C. Chamontin, C. Bella, F. Simian-Lermé
590 and C. Lionnet (Flow cytometry and PLATIM platforms of IFR128) for their helpful technical
591 assistance. This work benefited from the technical facilities of the CeCIL platform of IFR62. This
592 work would not have been possible without mAbs, plasmids, recombinant virus and/or cell
593 lines kindly provided by M. Billeter, C. Rice, M. L. Toribio, K. Takeuchi, A. Garcia-Sastre, J.
594 Hiscott, Y. Yanagi, E. Berger, and Schering-Plough (Dardilly, France). This work was supported
595 in part by grants from ANR (DG, ANR-MIME), INSERM, INCA-Canceropole 2004-2005 and
596 ARC 3637. D.L., F.H., J.D., T.D., and S.P. were supported by a fellowship from MENRT, ARC
597 and DGA, respectively. The authors have no conflicting financial interests.

598

599

600 **REFERENCES**

601

1. **Asselin-Paturel, C., G. Brizard, K. Chemin, A. Boonstra, A. O'Garra, A. Vicari, and G. Trinchieri.** 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. *J Exp Med* **201**:1157-67.
2. **Barchet, W., A. Krug, M. Cella, C. Newby, J. A. Fischer, A. Dzionek, A. Pekosz, and M. Colonna.** 2005. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. *Eur J Immunol* **35**:236-42.
3. **Bibeau-Poirier, A., S. P. Gravel, J. F. Clement, S. Rolland, G. Rodier, P. Coulombe, J. Hiscott, N. Grandvaux, S. Meloche, and M. J. Servant.** 2006. Involvement of the I κ B kinase (IKK)-related kinases tank-binding kinase 1/IKKi and cullin-based ubiquitin ligases in IFN regulatory factor-3 degradation. *J Immunol* **177**:5059-67.

4. **Bieback, K., E. Lien, I. M. Klagge, E. Avota, J. Schneider-Schaulies, W. P. Duprex, H. Wagner, C. J. Kirschning, V. Ter Meulen, and S. Schneider-Schaulies.** 2002. Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling. *J Virol* **76**:8729-36.
5. **Bonjardim, C. A.** 2005. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses--and viruses counteract IFN action. *Microbes Infect* **7**:569-78.
6. **Bratt, M. A., and W. R. Gallaher.** 1969. Preliminary analysis of the requirement for fusion from within and from without by Newcastle disease virus. *Proc. Natl. Acad. Sci. USA* **64**:537-543.
7. **Christiansen, D., P. Devaux, B. Reveil, A. Evlashev, B. Horvat, J. Lamy, C. Rabourdin-Combe, J. H. Cohen, and D. Gerlier.** 2000. Octamerization enables soluble CD46 receptor to neutralize measles virus in vitro and in vivo. *J Virol* **74**:4672-8.
8. **Coccia, E. M., M. Severa, E. Giacomini, D. Monneron, M. E. Remoli, I. Julkunen, M. Cella, R. Lande, and G. Uze.** 2004. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. *Eur J Immunol* **34**:796-805.
9. **Coelho, L. F., G. Magno de Freitas Almeida, F. J. Mennechet, A. Blangy, and G. Uze.** 2005. Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. *Proc Natl Acad Sci U S A* **102**:11917-22.
10. **Dalod, M., T. Hamilton, R. Salomon, T. P. Salazar-Mather, S. C. Henry, J. D. Hamilton, and C. A. Biron.** 2003. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. *J Exp Med* **197**:885-98.

11. **Diaz, M. O., S. Ziemin, M. M. Le Beau, P. Pitha, S. D. Smith, R. R. Chilcote, and J. D. Rowley.** 1988. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. *Proc Natl Acad Sci U S A* **85**:5259-63.
12. **Emeny, J. M., and M. J. Morgan.** 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. *J Gen Virol* **43**:247-52.
13. **Esolen, L. M., S. W. Park, J. M. Hardwick, and D. E. Griffin.** 1995. Apoptosis as a cause of death in measles virus-infected cells. *J Virol* **69**:3955-8.
14. **Esolen, L. M., B. J. Ward, T. R. Moench, and D. E. Griffin.** 1993. Infection of monocytes during measles. *J Infect Dis* **168**:47-52.
15. **Feng, X.** 2005. Regulatory roles and molecular signaling of TNF family members in osteoclasts. *Gene* **350**:1-13.
16. **Fernandez, E., A. Vicente, A. Zapata, B. Brera, J. J. Lozano, C. Martinez, and M. L. Toribio.** 1994. Establishment and characterization of cloned human thymic epithelial cell lines. Analysis of adhesion molecule expression and cytokine production. *Blood* **83**:3245-54.
17. **Fugier-Vivier, I., C. Servet-Delprat, P. Rivaller, M. C. Rissoan, Y. J. Liu, and C. Roubourdin-Combe.** 1997. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells. *J Exp Med* **186**:813-23.
18. **Gerlier, D., and N. Thomasset.** 1986. Use of MTT colorimetric assay to measure cell activation. *J Immunol Methods* **94**:57-63.
19. **Gerlier, D., H. Valentin, D. Laine, C. Roubourdin-Combe, and C. Servet-Delprat.** 2006. Subversion of the immune system by measles virus: a model for the intricate interplay between a virus and the human immune system, p. 225-292. *In* P. J. Lachman

and M. B. A. Oldstone (ed.), *Microbial Subversion of Host Immunity*. Caister Academic Press, Norwalk, UK.

20. **Gitlin, L., W. Barchet, S. Gilfillan, M. Cella, B. Beutler, R. A. Flavell, M. S. Diamond, and M. Colonna.** 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc Natl Acad Sci U S A* **103**:8459-64.
21. **Goodbourn, S., L. Didcock, and R. E. Randall.** 2000. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. *J Gen Virol* **81**:2341-64.
22. **Grosjean, I., C. Caux, C. Bella, I. Berger, F. Wild, J. Banchereau, and D. Kaiserlian.** 1997. Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. *J Exp Med* **186**:801-12.
23. **Guggenheim, M. A., R. M. Friedman, and A. S. Rabson.** 1968. Interferon: production by chick erythrocytes activated by cell fusion. *Science* **159**:542-3.
24. **Honda, K., S. Sakaguchi, C. Nakajima, A. Watanabe, H. Yanai, M. Matsumoto, T. Ohteki, T. Kaisho, A. Takaoka, S. Akira, T. Seya, and T. Taniguchi.** 2003. Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. *Proc Natl Acad Sci U S A* **100**:10872-7.
25. **Honda, K., A. Takaoka, and T. Taniguchi.** 2006. Type I interferon [correction of inteferon] gene induction by the interferon regulatory factor family of transcription factors. *Immunity* **25**:349-60.
26. **Honda, K., H. Yanai, T. Mizutani, H. Negishi, N. Shimada, N. Suzuki, Y. Ohba, A. Takaoka, W. C. Yeh, and T. Taniguchi.** 2004. Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. *Proc Natl Acad Sci U S A* **101**:15416-21.

27. **Honda, K., H. Yanai, H. Negishi, M. Asagiri, M. Sato, T. Mizutani, N. Shimada, Y. Ohba, A. Takaoka, N. Yoshida, and T. Taniguchi.** 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature* **434**:772-7.
28. **Hornung, V., J. Ellegast, S. Kim, K. Brzozka, A. Jung, H. Kato, H. Poeck, S. Akira, K. K. Conzelmann, M. Schlee, S. Endres, and G. Hartmann.** 2006. 5'-Triphosphate RNA is the ligand for RIG-I. *Science* **314**:994-7.
29. **Huppertz, B., C. Bartz, and M. Kokozidou.** 2006. Trophoblast fusion: fusogenic proteins, syncytins and ADAMs, and other prerequisites for syncytial fusion. *Micron* **37**:509-17.
30. **Izaguirre, A., B. J. Barnes, S. Amrute, W. S. Yeow, N. Megjugorac, J. Dai, D. Feng, E. Chung, P. M. Pitha, and P. Fitzgerald-Bocarsly.** 2003. Comparative analysis of IRF and IFN- α expression in human plasmacytoid and monocyte-derived dendritic cells. *J Leukoc Biol* **74**:1125-38.
31. **Juriscova, A., J. Detmar, and I. Caniggia.** 2005. Molecular mechanisms of trophoblast survival: from implantation to birth. *Birth Defects Res C Embryo Today* **75**:262-80.
32. **Karpova, A. Y., M. Trost, J. M. Murray, L. C. Cantley, and P. M. Howley.** 2002. Interferon regulatory factor-3 is an in vivo target of DNA-PK. *Proc Natl Acad Sci U S A* **99**:2818-23.
33. **Katayama, Y., A. Hirano, and T. C. Wong.** 2000. Human receptor for measles virus (CD46) enhances nitric oxide production and restricts virus replication in mouse macrophages by modulating production of alpha/beta interferon. *J Virol* **74**:1252-7.
34. **Kato, H., S. Sato, M. Yoneyama, M. Yamamoto, S. Uematsu, K. Matsui, T. Tsujimura, K. Takeda, T. Fujita, O. Takeuchi, and S. Akira.** 2005. Cell type-specific involvement of RIG-I in antiviral response. *Immunity* **23**:19-28.

35. **Kato, H., O. Takeuchi, S. Sato, M. Yoneyama, M. Yamamoto, K. Matsui, S. Uematsu, A. Jung, T. Kawai, K. J. Ishii, O. Yamaguchi, K. Otsu, T. Tsujimura, C. S. Koh, C. Reis e Sousa, Y. Matsuura, T. Fujita, and S. Akira.** 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**:101-5.
36. **Kawai, T., and S. Akira.** 2006. Innate immune recognition of viral infection. *Nat Immunol* **7**:131-7.
37. **Kawai, T., S. Sato, K. J. Ishii, C. Coban, H. Hemmi, M. Yamamoto, K. Terai, M. Matsuda, J. Inoue, S. Uematsu, O. Takeuchi, and S. Akira.** 2004. Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. *Nat Immunol* **5**:1061-8.
38. **Klagge, I. M., V. ter Meulen, and S. Schneider-Schaulies.** 2000. Measles virus-induced promotion of dendritic cell maturation by soluble mediators does not overcome the immunosuppressive activity of viral glycoproteins on the cell surface. *Eur J Immunol* **30**:2741-50.
39. **Krantic, S., C. Gimenez, and C. Roubardin-Combe.** 1995. Cell-to-cell contact via measles virus haemagglutinin-CD46 interaction triggers CD46 downregulation. *J. Gen. Virol.* **76**:2793-2800.
40. **Krug, A., A. R. French, W. Barchet, J. A. Fischer, A. Dzionek, J. T. Pingel, M. M. Orihuela, S. Akira, W. M. Yokoyama, and M. Colonna.** 2004. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. *Immunity* **21**:107-19.
41. **Kumar, H., T. Kawai, H. Kato, S. Sato, K. Takahashi, C. Coban, M. Yamamoto, S. Uematsu, K. J. Ishii, O. Takeuchi, and S. Akira.** 2006. Essential role of IPS-1 in innate immune responses against RNA viruses. *J Exp Med* **203**:1795-803.

42. **Lapenta, C., S. M. Santini, M. Spada, S. Donati, F. Urbani, D. Accapezzato, D. Franceschini, M. Andreotti, V. Barnaba, and F. Belardelli.** 2006. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. *Eur J Immunol* **36**:2046-60.
43. **Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D. F. Tough.** 2003. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. *Nat Immunol* **4**:1009-15.
44. **Le Bon, A., and D. F. Tough.** 2002. Links between innate and adaptive immunity via type I interferon. *Curr Opin Immunol* **14**:432-6.
45. **Leopardi, R., T. Hyypia, and R. Vainionpaa.** 1992. Effect of interferon-alpha on measles virus replication in human peripheral blood mononuclear cells. *Apmis* **100**:125-31.
46. **Lin, R., C. Heylbroeck, P. M. Pitha, and J. Hiscott.** 1998. Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. *Mol Cell Biol* **18**:2986-96.
47. **McChesney, M. B., C. J. Miller, P. A. Rota, Y. D. Zhu, L. Antipa, N. W. Lerche, R. Ahmed, and W. J. Bellini.** 1997. Experimental measles. I. Pathogenesis in the normal and the immunized host. *Virology* **233**:74-84.
48. **McCullough, K. C.** 1983. Characterization of a non-syncytiogenic autonomously replicating variant of measles virus. *J Gen Virol* **64 Pt 3**:749-54.
49. **Mrkic, B., B. Odermatt, M. A. Klein, M. A. Billeter, J. Pavlovic, and R. Cattaneo.** 2000. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. *J Virol* **74**:1364-72.

50. **Murabayashi, N., M. Kurita-Taniguchi, M. Ayata, M. Matsumoto, H. Ogura, and T. Seya.** 2002. Susceptibility of human dendritic cells (DCs) to measles virus (MV) depends on their activation stages in conjunction with the level of CDw150: role of Toll stimulators in DC maturation and MV amplification. *Microbes Infect* **4**:785-94.
51. **Naniche, D., T. F. Wild, C. Rabourdin-Combe, and D. Gerlier.** 1993. Measles virus haemagglutinin induces down-regulation of gp57/67, a molecule involved in virus binding. *J. Gen. Virol.* **74**:1073-1079.
52. **Naniche, D., A. Yeh, D. Eto, M. Manchester, R. M. Friedman, and M. B. Oldstone.** 2000. Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of Alpha/Beta interferon production. *J Virol* **74**:7478-84.
53. **Nishida, J., H. Yoshikura, T. Okabe, A. Urabe, and F. Takaku.** 1985. Interferons inhibit syncytia-forming ability and in vitro transmission of human T-cell leukemia virus. *Jpn J Cancer Res* **76**:249-52.
54. **Nozawa, Y., N. Ono, M. Abe, H. Sakuma, and H. Wakasa.** 1994. An immunohistochemical study of Warthin-Finkeldey cells in measles. *Pathol Int* **44**:442-7.
55. **Ohno, S., N. Ono, M. Takeda, K. Takeuchi, and Y. Yanagi.** 2004. Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. *J Gen Virol* **85**:2991-9.
56. **Panne, D., T. Maniatis, and S. C. Harrison.** 2007. An Atomic Model of the Interferon-beta Enhanceosome. *Cell* **129**:1111-23.
57. **Paz, S., Q. Sun, P. Nakhaei, R. Romieu-Mourez, D. Goubau, I. Julkunen, R. Lin, and J. Hiscott.** 2006. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. *Cell Mol Biol (Noisy-le-grand)* **52**:17-28.

58. **Perfettini, J. L., M. Castedo, T. Roumier, K. Andreau, R. Nardacci, M. Piacentini, and G. Kroemer.** 2005. Mechanisms of apoptosis induction by the HIV-1 envelope. *Cell Death Differ* **12 Suppl 1**:916-23.
59. **Peries, J. R., and C. Chany.** 1960. [Hemagglutinating and hemolytic activity of the measles virus.]. *C R Hebd Seances Acad Sci* **251**:820-1.
60. **Pichlmair, A., O. Schulz, C. P. Tan, T. I. Naslund, P. Liljestrom, F. Weber, and C. Reis e Sousa.** 2006. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**:997-1001.
61. **Plumet, S., and D. Gerlier.** 2005. Optimized SYBR green real-time PCR assay to quantify the absolute copy number of measles virus RNAs using gene specific primers. *J Virol Methods* **128**:79-87.
62. **Plumet, S., F. Herschke, J. M. Bourhis, H. Valentin, S. Longhi, and D. Gerlier.** 2007. Cytosolic 5'-Triphosphate Ended Viral Leader Transcript of Measles Virus as Activator of the RIG I-Mediated Interferon Response. *PLoS ONE* **2**:e279.
63. **Scheller, C., and C. Jassoy.** 2001. Syncytium formation amplifies apoptotic signals: a new view on apoptosis in HIV infection in vitro. *Virology* **282**:48-55.
64. **Schulz, O., S. S. Diebold, M. Chen, T. I. Naslund, M. A. Nolte, L. Alexopoulou, Y. T. Azuma, R. A. Flavell, P. Liljestrom, and C. Reis e Sousa.** 2005. Toll-like receptor 3 promotes cross-priming to virus-infected cells. *Nature* **433**:887-92.
65. **Servant, M. J., B. ten Oever, C. LePage, L. Conti, S. Gessani, I. Julkunen, R. Lin, and J. Hiscott.** 2001. Identification of distinct signaling pathways leading to the phosphorylation of interferon regulatory factor 3. *J Biol Chem* **276**:355-63.
66. **Servet-Delprat, C., P. O. Vidalain, H. Bausinger, S. Manie, F. Le Deist, O. Azocar, D. Hanau, A. Fischer, and C. Roubardin-Combe.** 2000. Measles virus induces abnormal differentiation of CD40 ligand-activated human dendritic cells. *J Immunol* **164**:1753-60.

67. **Servet-Delprat, C., P. O. Vidalain, H. Valentin, and C. Rabourdin-Combe.** 2003. Measles virus and dendritic cell functions: how specific response cohabits with immunosuppression. *Curr Top Microbiol Immunol* **276**:103-23.
68. **Severa, M., M. E. Remoli, E. Giacomini, J. Ragimbeau, R. Lande, G. Uze, S. Pellegrini, and E. M. Coccia.** 2006. Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. *J Leukoc Biol* **79**:1286-94.
69. **Shaffer, J. A., W. J. Bellini, and P. A. Rota.** 2003. The C protein of measles virus inhibits the type I interferon response. *Virology* **315**:389-97.
70. **Shingai, M., N. Inoue, T. Okuno, M. Okabe, T. Akazawa, Y. Miyamoto, M. Ayata, K. Honda, M. Kurita-Taniguchi, M. Matsumoto, H. Ogura, T. Taniguchi, and T. Seya.** 2005. Wild-type measles virus infection in human CD46/CD150-transgenic mice: CD11c-positive dendritic cells establish systemic viral infection. *J Immunol* **175**:3252-61.
71. **Spann, K. M., K. C. Tran, and P. L. Collins.** 2005. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. *J Virol* **79**:5353-62.
72. **Spielhofer, P., T. Bachi, T. Fehr, G. Christiansen, R. Cattaneo, K. Kaelin, M. A. Billeter, and H. Y. Naim.** 1998. Chimeric measles viruses with a foreign envelope. *J Virol* **72**:2150-9.
73. **Sumpter, R., Jr., Y. M. Loo, E. Foy, K. Li, M. Yoneyama, T. Fujita, S. M. Lemon, and M. Gale, Jr.** 2005. Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. *J Virol* **79**:2689-99.

74. **Sun, Q., L. Sun, H. H. Liu, X. Chen, R. B. Seth, J. Forman, and Z. J. Chen.** 2006. The specific and essential role of MAVS in antiviral innate immune responses. *Immunity* **24**:633-42.
75. **Taylor, P., T. Tamura, and K. Ozato.** 2006. IRF family proteins and type I interferon induction in dendritic cells. *Cell Res* **16**:134-40.
76. **Tajima, M., and S. Kudow.** 1976. Morphology of the Warthin-Finkeldey giant cells in monkeys with experimentally induced measles. *Acta Pathol Jpn* **26**:367-80.
77. **Takeda, M., S. Ohno, F. Seki, K. Hashimoto, N. Miyajima, K. Takeuchi, and Y. Yanagi.** 2005. Efficient rescue of measles virus from cloned cDNA using SLAM-expressing Chinese hamster ovary cells. *Virus Res* **108**:161-5.
78. **Takeuchi, K., N. Miyajima, N. Nagata, M. Takeda, and M. Tashiro.** 2003. Wild-type measles virus induces large syncytium formation in primary human small airway epithelial cells by a SLAM(CD150)-independent mechanism. *Virus Res* **94**:11-6.
79. **Tatsuo, H., N. Ono, K. Tanaka, and Y. Yanagi.** 2000. SLAM (CDw150) is a cellular receptor for measles virus. *Nature* **406**:893-7.
80. **Tomita, Y., and T. Kuwata.** 1981. Suppressive effects of interferon on cell fusion by Sendai virus. *J Gen Virol* **55**:289-95.
81. **Tomita, Y., and T. Kuwata.** 1979. Suppressive effects of interferon on syncytium formation by RD-114 virus in human transformed cells. *J Gen Virol* **43**:111-7.
82. **Valentin, H., O. Azocar, B. Horvat, R. Williems, R. Garrone, A. Evlashev, M. L. Toribio, and C. Roubardin-Combe.** 1999. Measles virus infection induces terminal differentiation of human thymic epithelial cells. *J Virol* **73**:2212-21.
83. **Vidalain, P. O., O. Azocar, H. Yagita, C. Roubardin-Combe, and C. Servet-Delprat.** 2001. Cytotoxic activity of human dendritic cells is differentially regulated by double-stranded RNA and CD40 ligand. *J Immunol* **167**:3765-72.

84. **Vidalain, P. O., D. Laine, Y. Zaffran, O. Azocar, C. Servet-Delprat, T. F. Wild, C. Rabourdin-Combe, and H. Valentin.** 2002. Interferons mediate terminal differentiation of human cortical thymic epithelial cells. *J Virol* **76**:6415-24.
85. **Volckaert-Vervliet, G., H. Heremans, M. De Ley, and A. Billiau.** 1978. Interferon induction and action in human lymphoblastoid cells infected with measles virus. *J Gen Virol* **41**:459-66.
86. **Wells, D. E., S. Chatterjee, M. J. Mulligan, and R. W. Compans.** 1991. Inhibition of human immunodeficiency virus type 1-induced cell fusion by recombinant human interferons. *J Virol* **65**:6325-30.
87. **Yoneyama, M., M. Kikuchi, T. Natsukawa, N. Shinobu, T. Imaizumi, M. Miyagishi, K. Taira, S. Akira, and T. Fujita.** 2004. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* **5**:730-7.

602 **FIGURE LEGENDS**

603

604 **Figure 1. Role of cell-cell fusion and MeV infection in the IFN- β response.** (A) Syncytia
605 formation scored as in Fig. S1, % of cells expressing MeV-N protein determined by flow
606 cytometry, and IFN- α/β production at 7 d.p.i. after infection of 293T/CD46⁺ cells with MeV (left
607 histogram), or recombinant chimerical MGV (right histogram), in the absence (dotted columns)
608 or presence of 10 $\mu\text{g/ml}$ of FIP (black columns). (B) Syncytia formation and accumulation of
609 MeV-N (upper panel) and IFN- β (lower panel) transcripts at 23 h.p.i. in 293T/CD46⁺ cells
610 transiently expressing H^{Ed}F (grid columns) or H^{KAF} (checked columns), respectively.
611 293T/CD46⁺ cells were infected with MGV with different MOI, then they were transfected at 2
612 h.p.i. (C) Dose response relationship of MeV-F transcription and IFN- β mRNA accumulation at
613 30 h.p.i. and IFN- α/β secretion at 3 d.p.i. with the MOI of MeV used to infect 293T/CD46⁺ cells
614 in the absence (dotted columns) or the presence of 10 $\mu\text{g/ml}$ FIP (black columns). Data are mean
615 values \pm s.d. from two to three independent experiments. ND: not detected. † indicates cell
616 cytotoxicity.

617

618 **Figure 2. Similar dose-dependent inhibition of cell-cell fusion and IFN- β gene**
619 **transcription by FIP.** 293T/CD46⁺ (A and C) or HeLa (B) cells were infected with MeV MOI of
620 1 prior to the addition of increasing amounts of FIP. (A) Micrographs of adherent cells stained
621 with Hoechst 33342 (magnification x400) at 72 h.p.i. Cells containing more than three nuclei
622 were considered as syncytia (white arrows). (B) Dose-dependent inhibition of cell-cell fusion by
623 FIP quantified by colorimetric β -Gal reporter gene expression assay. (C) Dose-dependent
624 inhibition of IFN- β mRNA accumulation by FIP at 30 h.p.i. Data are means \pm s.d. of triplicates.

625

626 **Figure 3. MeV-induced syncytia are dynamic entities with extended lifespan.** MeV-
627 infected 293T/CD46⁺ were cultured overnight in the presence of FIP, then cultured in the absence
628 (A, B) or the presence (C) of FIP (10 µg/ml) with recorded imaging for the next 60 h by time-
629 lapse microscopy. Images at a magnification x10 were extracted from Fig. S3Avideo.mov and
630 another video not shown at 12.83 h, 15 h, 16.66 h, 25.33 h, 32.5 h and 35.33 h recorded times.
631 (B) The duration of each stage was evaluated and expressed as mean ± s.d. of 17 microscopic
632 areas from three to four separate experiments. The frequency was estimated and indicated as the
633 proportion (%) that underwent transition through a given stage.

634

635 **Figure 4. Reciprocal trans-complementation of RIG-I and IFN-β deficient cells by**
636 **MeV-induced fusion.** RIG-I-deficient Huh7.5 or IFN-β-deficient Vero cells were infected with
637 MeV at MOI of 1, and co-cultured 8 h later with uninfected Vero and Huh7.5 cells (ratio 1:1),
638 respectively. The co-cultures were treated or not with 10 µg/ml of FIP. Cell-free supernatants
639 were collected at 30 and 60 h.p.i. to measure IFN-α/β production. At the end of the co-culture,
640 the cell monolayers were stained for fluorescent nuclei (magnification of x400) for counting
641 within every syncytium indicated by arrows. Data are from one representative experiment out of
642 two. ND: not detected.

643

644 **Figure 5. Unlike IFN-β gene, IRF-7 gene expression does not correlate with cell-cell**
645 **fusion.** 293T/CD46⁺ cells (left panels) and TEC (right panels) were either treated with 1000
646 IU/ml of rhIFN-β or infected with MeV MOI of 1 and cultured in the absence or presence of FIP
647 (10 µg/ml). Expression of IFN-β (upper dotted histograms) and IRF-7 (lower black histograms)

648 mRNA was quantified at 30 h.p.i. Data are from one representative experiment out of two or
649 three. ND: not detected.

650

651 **Figure 6. Mature, but not immature, DC exhibit fusion-dependent amplification of IFN-**
652 **α and IFN- β responses.** iDC and mDC were mock infected or infected with MeV strain at MOI
653 of 0.1, in the absence (dotted columns) or the presence (black columns) of FIP (100 μ g/ml).
654 Syncytia formation was scored for each condition as described in Fig. S1. (A) CD150 expression
655 on iDC and mDC cultures was analyzed by flow cytometry. (B) MeV-F transcript accumulation
656 in iDC and mDC cultures was measured at 3 d.p.i. (C) Secreted bioactive IFN- α/β in cell-free
657 supernatants collected at 3 d.p.i. IFN- α (D) and IFN- β (E) were measured by ELISA at 3 d.p.i.
658 Accumulation of (F) IFN- β and (G) IRF-7 transcripts at 3 d.p.i. in cDC cultures in the absence or
659 the presence of FIP (100 μ g/ml). Data are mean values from two to five separate experiments.
660 ND: not detected.

661

662 **Figure 7. Nuclear translocation of IRF-3 can be triggered within MeV-induced syncytia.**
663 (A) Nuclear translocation of GFP-IRF-3 within syncytia of 293T/CD46⁺ cells infected by MeV at
664 MOI of 1. Microphotographs (magnification x400) showing morphology (upper panels), Hoescht
665 labeled nuclei (middle panels) and GFP-IRF-3 labeled nuclei (bottom panels) at 30 h.p.i.
666 Micrographs (magnification of x400) of uninfected cells (mock) and cells infected with MeV in
667 the absence (MeV) or the presence of FIP (10 μ g/ml, MeV+FIP) are shown. Data are from one
668 representative experiment out of four. (B) Three-color overlays of confocal images showing the
669 distribution of GFP-IRF-3 (green), N (red), nuclei (Draq5, blue) in 293T/CD46⁺ cells infected or
670 not with MOI of 0.1 MeV in the presence or absence of FIP and transfected with GFP-IRF-3.
671 Syncytium images were taken at three morphological stages, flat adherent, retracting and smooth

672 ball, respectively. The whole set of one-color images used to build the overlays is shown in the
673 supplementary Fig.7SB. (C) Nuclear localization of endogenous IRF-3 in MGC derived from
674 MeV-infected mDC. mDC were mock-treated (left panel, magnification x63) or infected with
675 MeV at a MOI of 0.1 in the absence (middle panel, magnification x40) or the presence (right
676 panel, magnification x63) of FIP (100 µg/ml). 3 d.p.i., mDC culture were stained with anti-IRF-3
677 (green, left panel) and with nucleus staining (Hoechst 33343, blue). Cells were analyzed with an
678 axioplan microscope.

679

680 LEGENDS TO SUPPLEMENTAL DATA

681 **Figure S3Avideo.mov. Time-lapse microscopy of MeV-infected 293T/CD46⁺ in the**
682 **absence of FIP.** Animation Format: 380x331 million; sequence, FPS 3,75; Reading: IPS 9; Flow:
683 9,46 mbits/sec; Duration: 9,26 sec; Size and actual size: 100%: 338x331 pixels (see material and
684 methods and legends to Figure 3 for details).

685

686 **Figure S7Cvideo.mov. Nuclear endogenous IRF3 localisation within MeV-induced**
687 **MGC from mDC.** z stack compilation of images from MeV-infected mDC in the absence of FIP
688 (see material and methods).

689







Figure 1

A

MeV: - + + + + +
 FIP: 0 0 1 µg/ml 3 µg/ml 10 µg/ml 30 µg/ml

B**Fusion****C****IFN-β***Figure 2*






Figure 3




Figure 4






Figure 5





mock

+ FIP


MeV (1 MOI)

Nascent

Syncytia
Flat adherent

Smooth ball

B



mock

+ FIP

MeV (0.1 MOI)

Flat adherent

Syncytia
Retracting

Smooth ball

Figure 7 A,B




Figure 7C